SCHEMBL3531870

SCHEMBL3531870

Clc1ccc2[nH]nc(-c3nc4ccccc4[nH]3)c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 11/20 0.71
FGFR1 P11362 3/20 0.71
FLT1 P17948 2/20 0.71
CHEK1 O14757 3/20 0.58
ITK Q08881 2/20 0.56
CLK2 P49760 2/20 0.54
DYRK1A Q13627 2/20 0.54
WNT1 P04628 1/20 0.54
TGFBR1 P36897 1/20 0.54
CLK3 P49761 1/20 0.54
JAK2 O60674 2/20 0.53
CDK2 P24941 2/20 0.53
TYK2 P29597 2/20 0.53
JAK3 P52333 2/20 0.53
FLT3 P36888 2/20 0.53
PLK4 O00444 1/20 0.53
AURKA O14965 1/20 0.53
CHUK O15111 1/20 0.53
ROCK2 O75116 1/20 0.53
MAP4K4 O95819 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534644 0.89 FGFR1 (0.71) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL3542692 0.89 PDPK1 (0.56) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL3541234 0.86 ITK (0.71) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL3533024 0.84 PDPK1 (0.73) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL3532319 0.84 PDPK1 (0.51) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL3539728 0.84 KDM4E (0.58) PDPK1FGFR1FLT1CHEK1CLK2
SCHEMBL311148 0.84 FGFR1 (1.00) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL29714859 0.84 FGFR1 (1.00) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL3537965 0.83 ITK (0.76) PDPK1FGFR1FLT1CHEK1ITK
SCHEMBL4989411 0.83 PDPK1 (0.71) PDPK1FGFR1FLT1CHEK1ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK PDPK1 1862/4885FGFR1 886/4885FLT1 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.